Login / Signup

Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients.

Wathik AlsalimMargaretha PerssonBo Ahrén
Published in: Diabetes, obesity & metabolism (2018)
Treatment with DPP-4 inhibition with vildagliptin results in 15% lower fasting and postprandial glucagon levels compared to SGLT-2 inhibition with dapagliflozin. DPP-4 inhibition also induces more rapid insulin secretion and higher levels of intact incretin hormones, resulting in stronger feedback inhibition of incretin hormone secretion than SGLT-2 inhibition.
Keyphrases
  • type diabetes
  • newly diagnosed
  • end stage renal disease
  • blood glucose
  • insulin resistance
  • ejection fraction
  • smoking cessation
  • glycemic control
  • quantum dots